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Abstract
A variety of neurodegenerative disorders, including Alzheimer disease (AD), are associated
with neurofibrillary tangles composed of the tau protein, as well as toxic tau oligomers. Inhib-
itors of pathological tau aggregation, interrupting tau self-assembly, might be useful for the
development of therapeutics. Employing mirror image phage display with a large peptide
library (over 109 different peptides), we have identified tau fibril binding peptides consisting
of D-enantiomeric amino acids. D-enantiomeric peptides are extremely protease stable and
not or less immunogenic than L-peptides, and the suitability of D-peptides for in vivo applica-
tions have already been demonstrated. Phage display selections were performed using
fibrils of the D-enantiomeric hexapeptide VQIVYK, representing residues 306 to 311 of the
tau protein, as a target. VQIVYK has been demonstrated to be important for fibril formation
of the full lengths protein and forms fibrils by itself. Here, we report on D-enantiomeric pep-
tides, which bind to VQIVYK, tau isoforms like tau3RD (K19) as well as to full lengths tau
fibrils, and modulate the aggregation of the respective tau form. The peptides are able to
penetrate cells and might be interesting for therapeutic and diagnostic applications in AD
research.
Introduction
Alzheimer disease (AD) is the most common cause for dementia and a major global cause of
disability and dependency, raising significant personal and economic issues. In 2013, an esti-
mated 44.4 million people worldwide suffered from dementia, and this number is expected to
increase to 135.5 million in 2050 (http://www.alz.co.uk/research). Therapeutic options for AD
are currently limited. Palliative treatment can partially reduce the symptoms, and cognitive
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functions can be modestly maintained temporarily [1]. Acetylcholine esterase inhibitors like
Donepezil, Galantamine and the NMDA receptor antagonist Memantine have been approved
for clinical use in the treatment of cognitive symptoms, but no disease altering substances are
currently available [2–4].
Classical hallmarks of AD are aggregated protein deposits, i.e. senile plaques, composed of
the Amyloid-β (Aβ) peptide, and neurofibrillary tangles, composed of tau protein in the brain
tissue, as already described by Alois Alzheimer in the year 1907 [5].
Tau is a highly soluble microtubule associated protein playing a central role in stabilization
and organization of microtubules. It is abundant in neurons of the central nervous system,
where it can be particularly found in axons. There are six isoforms of tau in the human cere-
brospinal fluid, resulting from alternative splicing of 16 exons of the microtubule associated
protein tau (MAPT) gene, located on chromosome 17q21. The isoforms can be divided into
two major groups: 1) 4R tau, that contains 4 microtubule binding repeats (each 31–32 amino
acids long), and 2) 3R tau, that contains 3 microtubule binding repeats (lacking repeat 2; R2)
[6].
Tau protein aggregates pathologically in AD, but also in other neurodegenerative diseases
[7,8]. The distribution pattern of tau aggregates in the brain correlates well with cognitive
decline in AD and can be used for staging of the disease [9]. It is currently hypothesized that
amyloids propagate from cell to cell in a prion like manner [10,11].
Assembly of tau protein into paired helical filaments (PHFs) depends on a short sequence
motif, 306-VQIVYK-311, also termed PHF6, which is located at the beginning of the third
internal repeat. This motif coincides with the highest predicted β-structure potential in tau.
Point mutations in the hexapeptide region can decrease or increase aggregation, depending on
the change in β-propensity [12,13].
A variety of potential therapeutic substances for AD, like Aβ production inhibitors, Aβ
aggregation inhibitors or Aβ antibodies were tested successfully in vitro or in AD animal mod-
els, but many have failed in clinical trials due to side effects, or they have failed to demonstrate
significant therapeutic success [1]. The relationship between AD, Aβ and tau pathology is
poorly understood, but recent results suggest that tau is not simply a downstream process of
Aβ aggregation [14], and substances that inhibit tau aggregate formation might be interesting
for AD therapy development.
A variety of tau aggregation inhibiting substances have been described [15], but only one
compound, a derivative of methylene blue (LMTX), is at present under clinical investigation
(Phase III, www.alzorg.com). Currently, only two peptide compounds addressing tau pathol-
ogy are known. Davunetide (DAP) is an eight amino acid peptide derived from the activity-
dependent neuroprotective protein ADNP. It decreases tau phosphorylation and Aβ levels in
tau transgenic mice and 3 x transgenic (tg)-AD mice [16,17]. The intranasal formulation AL-
108 was tested to be safe in a 12 week phase placebo controlled trial in mild cognitive
impairment (MCI) patients [18]. However, DAP does not act as a tau aggregation inhibitor. In
2011, Sievers et al. developed a D-amino acid inhibitor of tau aggregation. The peptide
TLKIVW was designed on the tau 306-VQIVYK-311 steric zipper template in order to block
the addition of additional layers of VQIVYK. The apparent dissociation constant between the
D-peptide and VQIVYK was estimated to be 2 μM, and the inhibitor prevented aggregation of
PHF6 as well as of the tau constructs K12 and K19, both lacking the second repeat R2 [19].
Here, we describe the selection and characterization of novel tau fibril binding D-enantio-
meric peptides by mirror image page display. D-peptides were already shown to be suitable for
in vivo application as they are protease resistant and less immunogenic than the respective L-
peptides [20–22]. In addition, it was demonstrated that therapeutic peptides can be absorbed
systematically after oral administration [23]. Earlier, we reported on the identification and
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characterization of Aβ42 binding D-enantiomeric 12-mer peptides, also generated by mirror
image phage display [24–26]. The D-peptide D3 (amino acid sequence rprtrlhthrnr)
modulated Aβ aggregation and reduced Aβ42 cytotoxicity in cell culture. In APP/PS1 mouse
models, D3 reduced plaque load and cerebral inflammation after oral treatment, and the cog-
nitive behavior was significantly increased if compared to untreated control mice [27]. The tau
binding D-peptide compounds described here might be an interesting alternative to Aβ bind-
ing substances, or might be combined to achieve a drug with dual mode action.
Materials and Methods
Peptides
All peptides were obtained commercially as reversed phase high performance liquid chroma-
tography purified products (JPT Biotech, Berlin, Germany). For attachment of the FAM-
label, an additional lysine was added C-terminally to the respective peptide. The D- or L-
enantiomeric PHF6 peptide was obtained N-terminally acetylated, as charge distribution has
been shown to have a profound effect on the propensity of peptides to aggregate into filaments
and in the absence of N- and C-terminal charges, the blocked peptides closely mimic peptide
segments within the protein structure. Unacetylated PHF6 does not aggregate in vitro[28–30].
PHF6 fibrillization for phage display selection
The lyophilized D- or L-enantiomeric acetylated PHF6 peptide was solved in hexafluoro-
2-propanol (HFIP) to a molarity of 1.5 mM, respectively, to be used as peptide stock solution.
PHF6 fibrillization was started after dilution of 50 μM PHF6 peptide in 50 mM NaPi, pH 7.0.
PHF6 fibrillization was monitored using the ThioflavinT (ThT) assay. For ThT analysis, 50 μL
of the sample were separated and 5 μL ThT (10 μM) were added. The fluorescence measure-
ment was performed in black 96-well polystyrene microtiter plates (Thermo-Fischer Scientific,
Waltham, USA) at the fluorescence photometer POLARstar optima (BMG-Labtechnologies,
Ortenberg, Germany), excitation/emission wavelengths were set at 440/490 nm.
Phage display selection
The fibrillized D- or L-enantiomeric PHF6 peptide, prepared as described above, was immobi-
lized on polystyrene 96-well microtiter plates (Thermo-Fischer Scientific, Waltham, USA).
The assay plate to be coated was shaken for 1 hour at room temperature with gentle agitation.
Until the selection started, the coated assay plate was stored at 4˚C. Phage display was per-
formed using the Ph.D.-12 Phage Display Peptide Library Kit (New England Biolabs, Ypswich,
USA) according to the instructions of the manufacturer.
Single clone ELISA
The single-clone ELISA was required to identify single phages showing the strongest binding
to PHF6 fibrils. To perform ELISA analysis with phage supernatants, polystyrene 96-well
microtiter plates (Thermo-Fischer Scientific, Waltham, USA) were coated with PHF6 fibrils,
prepared as described above, but in a concentration of 100 μg/mL (126.6 μM). As controls,
only 50 mM NaPi, pH 7.0, without PHF6 fibrils was applied. 2 x 100 μL of each amplified
phage suspension was mixed with 100 μL blocking buffer (10 mg/mL BSA in TBS) and incu-
bated with gentle agitation for 20 minutes at room temperature to eliminate possible BSA-
binding phages. Then, the samples were transferred to PHF6 fibril coated wells and to the con-
trol wells. Subsequently, the plates were incubated for 1 hour at room temperature with gentle
agitation, followed by a 5-fold washing step with TBST (0.1% Tween-20 in Tris-buffered saline
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(TBS, 50 mM Tris, 150 mM NaCl, pH 7.6). The HRP/Anti-13 Monoclonal Conjugate kit stock
solution (GE-Healthcare, Little Chalfont, UK) was diluted 1:5000 and the antibodies were
incubated on the plates for 1 hour at room temperature, followed by 6-fold washing with
TBST. A 3,3’,5,5’-tetramethylbenzidine (TMB) tablet (Sigma-Aldrich, St. Louis, Missouri,
USA) was dissolved in 1 mL dimethyl sulfoxide (DMSO) and mixed with 9 mL phosphate-
citrate buffer (Sigma-Aldrich, St. Louis, Missouri, USA). 100 μL of the solution were trans-
ferred to the according sample wells. The horseradish peroxidase reaction was stopped by addi-
tion of 100 μL 2M H2SO4. The photometric quantification was carried out at OD450nm using a
POLARstar optima microtiter plate reader (BMG-Labtechnologies, Ortenberg, Germany).
Full lengths tau protein expression and purification
The gene for human tau isoform 6, tau40, has 1323 base pairs, encodes a protein of 441 amino
acids, which contains 4 terminal repeats which form the core of the microtubule binding
domain [31]. The respective tau40 gene was commercially synthesized and cloned into the
pET28A(+) vector (Genentech, San Francisco, USA) via NcoI / XhoI restrictions sites. The
C-terminal His-tag was deleted by addition of a stop codon before the encoding sequence. Pro-
tein expression and purification were performed according to Margittai et al. [32].
Fluorescence assays for inhibition of fibrillization
For PHF6 fibrillization inhibition assays, 25 μM PHF6 out of a 1.5 mM HFIP stock was incu-
bated in PBS buffer. After 2 days of incubation, ThT in a concentration of 10 μM was added to
the pre-incubated samples, followed by 30 minutes final incubation at room temperature. A
384-well microtiter plate was used for analysis; the wells were treated with gaseous nitrogen
and 50 μL sample volume were pipetted into each well. To quantify β-sheet based fibril forma-
tion, the relative fluorescence intensity was read out at 440/490 nm at a POLARstar optima
microtiter plate reader (BMG-Labtechnologies, Ortenberg, Germany) at room temperature.
The relative fluorescence was normalized to the positive controls, which were set to be 100%,
respectively.
Because of its high hydrophilicity, full lengths tau protein does not fibrillize spontaneously
in vitro, but in presence of acidic lipid micelles, it forms β-sheet based fibrils [33]. To obtain
fibrils, purified recombinant tau protein in 5 μM concentration, prepared as described above,
was incubated with 100 μM arachidonic acid (AA) in PBS buffer and incubated at room tem-
perature for a minimum of 24 hours. Negative controls were tested by incubation of the
recombinant protein in the absence of AA. To characterize the potential of the D-peptides to
inhibit tau fibril formation, they were added to the aggregation mix described above in a molar
ratio of 1:1 and 1:10 (tau:peptide), respectively.
The dose-dependent inhibition of tau aggregation was performed in the Mandelkow lab
using Thioflavin S (ThS) and the tau3RD construct K19, as already described before [34,35].
Dynamic light scattering
Dynamic light scattering (DLS) enables the determination of the hydrodynamic radius of mol-
ecules and is frequently used to investigate the influence of fibrillization inhibiting substances.
Recombinant tau protein was dissolved in PBS and in presence of 100 μM AA to a concentra-
tion of 1 mg/ml (21.8 μM). The respective peptide was added in a molar ratio of 1:10 (tau to
peptide). As a positive control, tau without peptides was tested after addition of AA, and as
negative control, it was tested without addition of neither peptides nor AA. The state of aggre-
gation was determined after 24 hours. DLS measurements were carried out with a DynaPro
DLS system (Protein Solutions, Lakewood, NJ, USA) at 20˚C, a fixed angle (90˚) and a cuvette
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path lengths of 3 mm. The acquisition time was 5 seconds with a read interval of 1 second and
laser power 100% at 20˚C, using a 655.6 nm (13 mW) laser. Analysis and averaging of the col-
lected data was performed with the software Dynamic V6 (Protein Solutions). By using calcu-
lated autocorrelation functions, a regularization fit was performed in order to obtain the size
distribution profile. The histograms of all measurements showed mostly monodisperse size
distributions. The calculated hydrodynamic radii of the negative control, the tau monomer
without addition of peptides nor AA, was used as the standard. The radii of tau in the presence
of AA and peptides were normalized to the negative control and plotted as a quotient in loga-
rithmic scale. One should keep in mind that the hydrodynamic radii are approximated on the
basis of spheres. Mature fibrils in fact often display a rod-like or fibrous morphology, and it
should be noted that in addition to this approximation the ability to accurately extract particle
size with dynamic light scattering diminishes with increased aggregate size and conforma-
tional heterogeneity [36].
Penetration of peptides into cells
The peptides were obtained with a 6-Carboxyfluorescein (FAM) label, linked via a C-terminal
lysine, to assay their ability to enter N2a cells expressing a variant of tau protein (construct
tau4RDΔK280, derived from the 4-repeat domain) in a regulatable fashion [37]. The cells were
incubated in the presence of the peptides for two hours (short term uptake) and four days
(long term uptake and stability) at concentrations of 60 μM. After incubation the cells were
fixed on glass cover slips and monitored by a confocal microscope (Fluoview 1000, Olympus).
The localizations of the D-peptides were detected by their FAM-label (excitation: 488 nm,
emission: 520 nm). In addition, cell nuclei were stained with TOPRO3 dye (excitation: 633
nm, emission: 660–670 nm). Representative pictures were taken with magnifications of
10-times for overview and 60- and 120-times for more detailed analysis.
In silico modelling
Modeling of the APT and TD28 peptides complexes with PHF6 was guided by a previous
model of PHF6 with the D-peptide TLKIVW published by Sievers et al. [19]. We reconstructed
the complex based on the crystal structure of unliganded PHF6 (PDB code 2ON9 [38]) by
docking the D-peptide TLKIVW in an extended conformation to PHF6 using the same hydro-
gen bond register described by Sievers et al. [19]. APT and TD28 were then modeled in the
same extended geometry present in the TLKIVW peptide. The binding register was set accord-
ing to the position of a conserved basic residue present in all three peptides. Modeling was per-
formed with Sybyl 7.3 (Tripos Inc., St. Louis, USA) and UCSF Chimera [39]. Visual inspection
of the complexes between the PHF6 oligomers and the docked peptides was performed with
VMD [40].
Results
Selection of PHF6 binding peptides
As it was hardly possible to synthesize D-enantiomeric full lengths tau protein (lengths 441
amino acids) for mirror image phage display, we realized the selections of a peptide library
encoding more than 1 x 109 different random 12-amino acid sequences with fibrils of the D-
enantiomeric hexapeptide VQIVYK (D-PHF6) as the target. In addition, we performed selec-
tions with L-enantiomeric PHF6 fibrils under same conditions. The fragment VQIVYK has
been demonstrated to be indispensable for tau aggregation and forms itself fibrils, [12,13],
therefore we expected the resulting peptides to bind fibrils of the full lengths tau protein. The
Tau Binding D-Peptides
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location of the PHF6 sequence in the tau protein is depicted in Fig 1A. The principle of the
mirror image phage display selection is shown in Fig 1B. To prepare PHF6 fibrils for the selec-
tion procedure, PHF6 was HFIP treated and incubated in sodium phosphate buffer for at least
two hours. Fibrillization was monitored using ThT-fluorescence assays, and the resulting
fibrils were immobilized in microtiter plates. Thioflavin is a benzothiazole dye that exhibits
enhanced fluorescence upon binding to amyloid fibrils. The quantity of the bound dye is deter-
mined by measuring the relative fluorescence [41].
After four rounds of biopanning, single phages of the finally enriched phage dilution were
tested for their ability to bind PHF6 fibrils using single phage ELISA, and the peptide
sequences of promising phages were determined by DNA sequence analysis of the respective
genome region. Interestingly, not one single dominating amino acid sequence or consensus
sequence was found in 23 sequences, but some sequences were selected twice or three-fold. 10
peptides were chosen for further characterization and for testing their potential to inhibit tau
aggregation. The peptide sequences are listed in Table 1. All peptide sequences found after
selection were compared to already known peptide sequences listed in the SAROTUP database
(“Scanner And Reporter Of Target-Unrelated Peptides", a suite of web tools which can be used
to scan, report and exclude possible target-unrelated peptides from biopanning results: http://
immunet.cn/sarotup/) and the PepBank database (database of peptides based on sequence text
mining and public peptide data sources: http://pepbank.mgh.harvard.edu/), but no hits were
documented.
In vitro characterization of PHF6 and tau aggregation inhibition
To investigate the potential of the selected peptides to inhibit fibrillization of PHF6, the tau
construct K19 and full lengths tau, we performed Thioflavin fluorescence assays. The fibril
Fig 1. Tau constructs and principle of the mirror image phage display selection. (A) The largest human tau
isoform in the central nervous systems contains four microtubule binding repeats, whereas the tau construct tau3RD
(K19) lacks repeat 2 [42]. PHF6, consisting of amino acids 306 to 311, is located at the beginning of repeat three. (B) The
D-enantiomeric form of PHF6 was synthesized. (C) After fibrillization, the D-enantiomeric fibrils were used for phage
display (D). (E) An L-peptide, binding to the D-enantiomeric PHF6 fibrils, was selected. (F) The D-enantiomeric version of
the selected L-peptide was synthesized, which (G) will bind to the L-enantiomeric form of the target, regular PHF6 fibrils.
doi:10.1371/journal.pone.0167432.g001
Tau Binding D-Peptides
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formation of acetylated PHF6 was monitored in the presence and absence of a one- or tenfold
molar access of the respective peptide. The fluorescence of the control sample without peptide
reached a saturation level after two hours of incubation (Fig 2A), therefore, the value after 2
hours was set to be 100%. The results of the peptides selected in this study were compared to
the performance of the TLKIVW peptide described by Sievers et al. [19]. As listed in Table 1,
the peptides TD2, TD12, TL8, and TL18 did not show any significant effect on PHF6 fibril for-
mation. TL20 even seemed to increase fibrillization of PHF6. These respective peptides were
not used for further investigation. As can be seen in Fig 2B, all other selected peptides reduced
PHF6 fibril formation significantly, especially in a ratio of 1:10. The peptide KNT did not
inhibit PHF6 fibrillization in a ratio of 1:1 and had only a minor effect in a ratio of 1:10. None
of the peptides showed self-fibrillization tendencies in the control sample without PHF6 under
assay procedure conditions. To investigate if the relatively small, 12-meric peptides could also
inhibit full lengths tau aggregation, similar Thioflavin assays as described above were per-
formed with full lengths tau. Tau aggregation was initiated by addition of arachidonic acid
(AA) (see Fig 2C), and tau in a concentration of 5 μM was incubated in absence or presence of
the respective peptide in a molar ratio of 1:1 or 1:10. After three hours of incubation, the fluo-
rescence of the tau-only control sample reached a saturation level, and the value of fluores-
cence was set to 100%. In this assay, we could demonstrate a weak effect of the TLKIVW
peptide, all peptides selected in this study clearly inhibited fibril formation of the tau protein.
As the D-peptides were selected using PHF6 fibrils, we ordered FAM labeled versions of the
promising peptides to confirm their binding to full lengths tau protein and its fibrils. For
APT-Lys(FAM)-NH2, KNT-Lys(FAM)-NH2, LPS-Lys(FAM)-NH2, TD28-Lys(FAM)-NH2,
TD28rev-Lys(FAM)-NH2 as well as for D-tlkivw-Lys(FAM)-NH2 binding could be demon-
strated for tau monomers as well as for tau fibrils. No significant difference could be detected
between the binding to the different conformers. Except for APT-Lys(FAM)-NH2, all peptides
showed a minimal preference for tau monomers, probably due to better accessibility of the
PHF6 motif, which might partly be hidden inside the fibrils. The ELISA signal was highest for
KNT-Lys(FAM)-NH2, TD28-Lys(FAM)-NH2, as well as the positive control peptide D-tlkivw-
Lys(FAM)-NH2, see S1 Fig.
Next, we tested the peptides APT, KNT, LPS, TL28, TD28, and TD28rev for their ability to
inhibit the aggregation of tau3RD (three repeat domain construct of tau protein, also termed
K19, see Fig 1) in vitro as measured by ThS fluorescence [35,42]. In addition, we have
Table 1. Selected peptides tested for their potential to inhibit PHF6 fibrillization using ThT assay.
Name Sequence Selection Inhibition of PHF6 fibrillization
APT D-aptllrlhslga D-vqivyk +
KNT d-kntpqhrklrls D-vqivyk +
TL28 l-TTSLQMRLYYPP L-vqivyk +
TD28 d-ttslqmrlyypp D-vqivyk +
TD28rev d-ppyylrmqlstt D-vqivyk +
Positive Control d-tlkivw [19] D-vqivyk +
TD2 d-stfdpltlhktr D-vqivyk -
TD12 d-dknhvspvqiyk D-vqivyk +/-
TL8 l-sshnvnggtwgs L-vqivyk +/-
TL18 l-mnlsngevynak L-vqivyk -
All peptides listed in the table were tested for their potential to inhibit PHF6 fibrillization using ThT assay. (+/-) indicates comparably low inhibition of PHF6
fibril formation, (-) indicates that the peptide showed no effect on fibril formation.
doi:10.1371/journal.pone.0167432.t001
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determined the half maximal effect concentrations of the peptides. K19 was chosen because it
fibrillizes reliably at low micromolar concentrations in the presence of the polyanionic cofactor
heparin and resembles Alzheimer paired helical filaments [12,13]. The results can be seen in
Table 2 and Fig 3. The half maximal effects were achieved at the following concentrations:
Fig 2. ThT assays for characterization of the peptides abilities to inhibit fibril formation. (A) PHF6
fibrillizes spontaneously within 2 hours. The assay was performed using 25 μM PHF6 peptide in PBS with
10 μM ThT (black line). PBS and 10 μM ThT without addition of PHF6 was used as control (grey line).
Fluorescence was measured at 490 nm in relative units (mean +/- standard deviations of results, five
replicates per run. (B) PHF6 fibrillization was inhibited by the selected peptides. The respective peptide was
added in concentrations of 25 or 250 μM to 25 μM PHF6 samples, respectively. Upon addition of ThT,
fluorescence was measured at 490 nm in relative units (mean +/- standard deviations of results, five replicates
per run). The relative fluorescence for the PHF6 only control after 2 hours incubation (saturation level) was set
at 100%. *: p < 0.05; **: p < 0.0005; students t-test. (C) Recombinant full lengths tau protein fibrillizes under
assay conditions. 5 μM tau, 100 μM AA and 10 μM ThT were incubated in PBS (black line). As a negative
control, 5 μM tau was incubated in PBS with ThT, without addition of AA. Fluorescence was measured at
490 nm in relative units (mean +/- standard deviations of results, five replicates per run). The relative
fluorescence of a PBS sample with 100 mM AA was subtracted. (D) ThT assays were employed to
characterize the abilities of peptides to inhibit full lengths tau fibril formation. The respective peptide was
added in concentrations of 50 μM peptide to 5 μM tau and 100 M AA. Upon addition of ThT, fluorescence was
measured at 490 nm in relative units (mean +/- standard deviations of results, five replicates per run). The
relative fluorescence for the tau and AA control without peptides and after 2.5 hours incubation (saturation
level) was set at 100%. *: p < 0.05; **: p < 0.0005; students t-test.
doi:10.1371/journal.pone.0167432.g002
Table 2. Half maximal effect concentrations.
Peptide name Half maximal effect concentration [μM]
TD28 7.9
TD28rev 96.2
APT 139.6
KNT 182.8
TL28 >200
Inhibition curves of tau3RD fibril formation were performed in vitro by ThS assays. Tau3RD (K19) samples
treated with the D-peptides showed a decreasing ThS signal at increasing peptide concentrations, indicating
an inhibition of aggregation.
doi:10.1371/journal.pone.0167432.t002
Tau Binding D-Peptides
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TD28 (7.9 μM), TD28rev (96.2 μM), APT (139.6 μM), KNT (182.8 μM), LPS (> 200 μM),
TL28 (> 200 μM).
At peptide concentrations > 100 μM, an increasing ThS fluorescence for the cases of TD28
and TD28rev were observed. This might be explained by direct binding of ThS to these pep-
tides (possibly due to self-aggregation). In contrast to the PHF6 aggregation inhibition assay,
this effect was already visible for TD28rev and ThS in the absence of tau protein under this
assay procedure conditions (data not shown).
We wanted to confirm the results of the ThS studies by DLS (see Fig 4). Full lengths tau pro-
tein was dissolved to 1 mg/mL in PBS (21.8 μM). 100 μM AA were added as well as the respec-
tive peptide in a molar ratio of 1:10 (tau:peptide). The state of aggregation was determined at
different time points from 1 hour to 24 hours. While peptides APT, KNT and LPS inhibited
formation of tau aggregates, TD28 and TD28rev induced the formation of large particles,
again possibly due to self-aggregation under the given experimental conditions. TL28 and the
TLKIVW peptide did not show any inhibitory effects.
Ability of the peptides to penetrate cells
To be effective as therapeutics, peptides will have to be able to cross the blood brain barrier
and the cell membranes of neurons. In this study, we tested FAM-labeled versions of the D-
peptides for their ability to enter N2a cells expressing a variant of tau protein (derived from
the repeat domain) in a regulatable fashion [37]. The cells were incubated in the presence of
the peptides for two hours (short term uptake) and four days (long term uptake and stability)
Fig 3. ThS inhibition assays were performed in vitro using the tau3RD construct K19. Dose-response
curves for inhibition of tau aggregation were plotted as percentage of the untreated control. Samples treated
with D-peptides show a decreasing ThS signal at increasing concentrations, indicating an inhibition of tau
aggregation.
doi:10.1371/journal.pone.0167432.g003
Tau Binding D-Peptides
PLOS ONE | DOI:10.1371/journal.pone.0167432 December 22, 2016 9 / 18
at concentrations of 60 μM. After incubation the cells were fixed on glass cover slips and moni-
tored by a confocal microscope. The localizations of the D-peptides were detected by their
FAM-label, in addition cell nuclei were stained with TOPRO3 dye. Representative pictures for
APT-FAM, KNT-FAM and TD28-FAM in 60-times magnification are summarized in Fig 5.
Cell compartments, where labeled D-peptides could be detected, are summarized in Table 3.
Representative confocal z-stacks for peptides KNT-FAM and TD28-FAM with magnified
frame 10 are shown in S2 and S3 Figs. The peptide KNT-FAM shows accumulations of punc-
tate foci in the cytosol and separately some foci beneath the cell membrane (green dots) but no
localization in the nucleus (S2B Fig, arrows). In contrast, the distribution of TD28-FAM is
more diffuse over the whole cell body. The fluorescence appears near the membrane, in the
cytosol, and in the nucleus (here merged with the red nucleus staining as yellow; S3B Fig,
arrows).
The treatment of tau expressing N2a cells with FAM-labeled D-peptides led in all cases to an
accumulation of peptides in the cytoplasm, visible at the latest after 4 days of incubation. We
conclude that all D-peptides are able to penetrate the cell membrane, in which the APT-FAM
peptide seemed to have the worst cell penetration properties. In some cases (APT-FAM,
TD28-FAM, TD28rev-FAM), there was an overlap of peptide and nuclei staining, suggesting
penetration into the nucleus. On the other hand, many of the ‘peptide-positive’ cells appeared
to have lost their nuclei, which may reflect potential cytotoxicity of this peptide. In addition,
for TD28 and TD28rev precipitation of the peptides in the medium was observed.
To obtain first hints on the effect of treatment on the inducible N2aTau4RDΔK280 cells with
D-peptides, we incubated the cells with 10 to 60 μM of the respective peptide in presence of
Fig 4. Effect of the selected peptides on tau aggregation, measured by DLS. Recombinant tau was
dissolved in PBS to a concentration of 21.8 μM (1 mg/ml). As positive control, AA was added to a
concentration of 100 μM. The peptides were added in a ratio of 1:10 (tau:peptide) and 100 μM AA. All samples
were incubated for 24 hours. DLS was performed with an acquisition time of 5 seconds for 3 minutes at room
temperature. The ratio of the hydrodynamic radii of tau protein in the presence of the peptides to tau fibrils
(positive control) was calculated. The error was below 10% for all measurements, the mass was 99%.
doi:10.1371/journal.pone.0167432.g004
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THS and doxycyclin, except for the untreated control, and quantified the ThS fluorescence
by fluorescence-activated cell sorting (FACS). Cells with ThS-positive aggregates were mea-
sured by the fluorescent signal intensity in the green channel (excitation: 495 nm, emission:
519 nm). The amount of ThS-positive cells in the compound-untreated DMSO control was set
to 100%. The bar diagram in S4 Fig shows the relative amount of Thioflavin S positive cells
when treated with increasing amounts of the tested D-peptides for 4 days, compared to the
untreated control, as quantified by FACS. In the case of peptides APT and KNT there was a
small decrease in the number of ThS-positive cells (e.g. 8.5% at 60 μM APT, and 9.5% at 20 μM
KNT-peptide), whereas treatment with TL28 shows no reduction of ThS-positive cells. In con-
trast the treatment with TD28rev (10–30 μM) increased the number of ThS-positive cells up
to 240% compared with the untreated control. This seems to be a non-specific effect because
the whole cell population (ThS-positive and -negative cells) shifted to higher fluorescence
intensities when treated with 30 μM TD28rev comparing to the control samples (data not
shown).
In silico analysis of binding mode
The crystal structure of the PHF6 peptide (residues 306–311 of tau) revealed a characteristic
steric-zipper motif comprising two interacting stacks of β-strands that run perpendicular to
the fibril axis [38] (Fig 6A). This structure already provided a basis for the rational design of a
D-peptidic inhibitor with the sequence TLKIVW [19]. Structural models of APT and TD28 in
complex with a fibrillar PHF6 oligomer show similarities to the TLKIVW-PHF6 complex (see
Fig 6): For all three peptides, binding in a parallel β-sheet conformation allows the formation
of stabilizing backbone hydrogen bonds to PHF6. Similar to TLKIVW, APT and TD28 can
establish a favorable side chain contact between the central positively charged residue (R in
APT and TD28, K in TLKIVW) and Q307 of PHF6. Sievers et al. suggested steric repulsion
Fig 5. Inducible N2aTau4RDΔK280 cells were incubated with 60 μM of the respective, FAM-labeled peptide for two
hours and four days. After incubation, the cells were fixed on glass cover slips and the locations of the respective peptide
were detected by the FAM-label (green). In addition, cell nuclei were stained with TOPRO3 dye (red). Here, representative
pictures for APT-FAM, KNT-FAM and TD28-FAM are shown in 60 times magnification. Scale bar: 30 μm.
doi:10.1371/journal.pone.0167432.g005
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between L2 of TLK and V306/I308 of the second stack of β-strands as key feature blocking
fibril growth [19]. The same type of clash is also formed by residues L5 of APT and M6 of
TD28, which are located at the structurally equivalent position to L2 of TLKIVW (Fig 6B–6D).
Compared to TLKIVW, APT and TD28 exhibit additional steric clashes with Y310 formed by
L4 of TD28 and by T3 of APT (Fig 6C and 6D), suggesting that these peptides can more
potently hinder PHF6 aggregation.
Table 3. Cell penetration of the peptides.
Peptide name 2 hours incubation 4 days incubation
membrane cytosol nuclei membrane cytosol nuclei
APT-Lys(FAM)-NH2 + +/- - + + +/-
KNT-Lys(FAM)-NH2 + + - + + -
LPS-Lys(FAM)-NH2 + + - + + -
TD28-Lys(FAM)-NH2 + + +/- + + +
TD28rev-Lys(FAM)-NH2 + + + + + +
60 μM of the respective FAM labeled peptide was incubated with inducible N2aTau4RDΔK280 cells [37]. After incubation of 2 hours or 4 days the cells were
fixed on glass cover slips and monitored by a confocal microscope. The localizations of the peptides were detected by their FAM-label. In addition, cell
nuclei were stained with TOPRO3 dye. Cell compartments where fluorescence of the label was detected are summarized here. Representative example
pictures with 60 times magnification are illustrated in Fig 5.
doi:10.1371/journal.pone.0167432.t003
Fig 6. Structure of the tau fibril and binding mode of different D-peptides. (A) Crystal structure of the
steric zipper formed by the PHF6 peptide. The first and last residue for each of the two stacks of interacting β-
sheet is labeled. The individual layers of β-sheet within each stack are gradually colored from red to blue. (B)
Binding mode of the TLKIVW peptide according to Sievers et al. [19]. The side chain interaction between K3
and Q307 is marked by a green arrow. The red ellipse denotes steric repulsion between L2 of TLKIVW and
V306/I308 of the second stack of β-strands. Peptide residues are labeled in italic. (C) Binding mode of the
TD28 peptide. Same type of presentation as in (B); an additional repulsive interaction formed between L4 and
Y310 is highlighted by a magenta ellipse. (D) Binding mode of the APT peptide. Same type of presentation as
in (B); an additional repulsive interaction formed between T3 and Y310 is highlighted by a magenta ellipse.
doi:10.1371/journal.pone.0167432.g006
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Discussion
Currently, no disease modifying therapeutics for tauopathies are available. In the present
study, we have demonstrated that PHF6 binding D-enantiomeric peptides, selected by mirror
image phage display, inhibit PHF6 as well as full lengths tau aggregation. In addition, the abili-
ties of the selected peptides to penetrate cells were shown.
Currently, only one peptide compound addressing tau pathology by a signaling mechanism,
Davunetide (DAP), decreasing tau phosphorylation and Aβ levels in tau transgenic mice, is
known [16,17]. Another D-enantiomeric peptide, TLKIVW, was rationally designed by Sievers
and colleagues to inhibit tau fibril formation [19]. However, during the past years, several pep-
tide inhibitors of Aβ aggregation have been investigated for their applicability as new therapeu-
tic lead compounds. Only very few were proven to be effective in mouse models [43]. Despite
the advantages of peptides, like high diversity, combined with their simplicity, specificity, high
biological activity and low toxicity [44,45], peptides are susceptible to proteolytic degradation
and in general are not stable in blood. Additionally, peptides are known not to cross mem-
branes very well [46,47]. The direct intracellular delivery of peptides has been difficult to
achieve, due primarily to the bioavailability barrier of the plasma membrane, which prevents
the uptake of macromolecules like peptides by limiting their passive entry [48].
Several strategies were already applied to overcome high protease susceptibility of peptides
and to improve blood brain barrier permeability. One strategy to improve the peptide stability
is the use of D-enantiomeric amino acids, which are considered to be rather protease resistant
and often less immunogenic than the respective L-peptides [20–22]. In addition, D-peptides
were described to be absorbed systematically after oral administration [23], also shown for the
Aβ oligomer precipitating D-enantiomeric peptide D3 in AD mouse models [27,49]. The PHF6
binding, D-enantiomeric peptides developed in this study were demonstrated to cross the
membranes of N2a cells. The mechanism of penetration is unclear yet. Peptides do in general
not cross membranes very well, but several classes of cell penetrating peptides have been dis-
covered, including naturally occurring transcription factor domain as penetratin, HIV-Tat or
synthetic cationic peptides [50–52]. However, as in our experiments, in some cases an overlap
of peptide and nuclei staining was visible, suggesting penetration into the nucleus, and on the
other hand, many of the ‘peptide-positive’ cells appeared to have lost their nuclei which may
reflect potential cytotoxicity of this peptide, cell toxicity assays will have to be performed in
future. Whether the peptides also will cross the blood brain barrier of e.g. AD mouse models,
will be subject of a further future study.
Phage display selections for this study were performed using fibrils of the D-enantiomeric
hexapeptide VQIVYK, representing residues 306 to 311 of the tau protein, as a target. VQI-
VYK was shown to be crucial for tau fibrillization and is widely used as a model for tau aggre-
gation [19,53–56]. As expected, the selected peptides also bound to full length tau protein
(S1 Fig) and inhibited the fibrillization of tau3RD and the full lengths tau protein in concentra-
tions which are typical for peptide inhibitors [19,25,27]. We also could show a slight effect of
peptide treatment on inducible N2aTau4RDΔK280 cells, here, however, further investigation is
necessary and planned for future studies.
At the moment, we only can speculate about the mechanism of action. As can be seen in
S1 Fig, the peptides bind similarly well to full length tau monomers as to its fibrils. For the
selection of the peptides, we have used PHF6 fibers, but this does not exclude the sequence spe-
cific binding of the resulting peptides to monomers, as conformer selectivity was not intended
in the selection process.
As the peptides were selected against the VQIVYK motif, they might block the addition of
further building blocks as also suggested for the TLKIVW peptide [19]. This theory is
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supported by molecular modeling, which suggested that APT and TD28 interact with PHF6 in
an analogous fashion than TLKIVW and prevent fibril formation by a similar mechanism.
Their enhanced activity against full lengths tau fibrils most likely results from the larger steric
repulsion caused by additional residues of the longer APT and TD28 peptides. These addi-
tional residues cause steric repulsion within PHF6 segment (Fig 6B–6D) and probably also
with adjacent residues outside the PHF6 stretch. The latter tau residues could not be included
in the present model due to a lack of a suitable template structure. As the small fiber forming
domain VQIVYK and its vicinity is covered by a large fuzzy coat in full lengths tau fibrils [57],
which could restrict access of peptides, the inhibitory effect on fibril formation might be due
to binding of the peptides to pre-fibril forms of tau, keeping them in a blocked anti-aggregant
state.
With respect to the formation of additional interactions, TD28 contains an interesting can-
didate stretch (‘YYPP’) that is rich in prolines and aromatic amino acids (Fig 6C). This stretch
might act as a tau β-sheet breaker in a similar fashion as the LPFFD peptide designed against
amyloid-β [58]. However, TD28 and TD28rev showed tendencies to self-aggregate under cer-
tain experimental conditions where the peptide concentrations are high (if compared to later
potential in vivo studies). The high self-assembly tendency of proline- and tyrosine-rich tripep-
tides [59] suggests that the YYPP motif of TD28/TD28rev might be involved in the formation
of the larger amorphous particles experimentally observed for TD28/TD28rev, but not for the
other tau ligands.
We have selected D-enantiomeric peptides in order to inhibit the fibril formation of tau.
Future experimental work will be needed to reveal the mechanism of action of the peptides
selected in this study and to investigate their potential for future therapeutic applications. In
addition, to date, it is not clear which of the tau conformers (monomer, oligomer, fibril) is the
best target for therapeutic intervention. It was recently suggested that tau oligomers are the
more toxic species in AD progression and these oligomers might be involved in the spreading
of tau pathology from cell to cell [10,11]. In future, we plan to select peptides, which bind spe-
cifically to tau monomers and oligomers. Similar species specific peptides were earlier devel-
oped for conformers of the Aβ peptide [60,61]. Novel tau conformer specific peptides should
be used to investigate in which stage of AD the inhibition of tau aggregation is reasonable and
therapeutically helpful.
Supporting Information
S1 Fig. ELISA experiment demonstrating the binding of the selected peptides, as well as of
a positive control, to tau monomers and fibrils in 5 μg/mL concentration. As a negative
control, PBS pH 7.4 containing 1% BSA was incubated in the wells instead of tau protein solu-
tion. After incubation with 20 μg/mL of the respective peptide wit FAM-label, a horseradish
peroxidase-conjugated sheep anti FITC secondary antibody was used for detection of
bound peptide. The mean of three OD values (at 405 nm) is given, as well as the standard devi-
ation.
(TIF)
S2 Fig. Representative distribution of KNT-FAM in the N2aK18ΔK280 cell body after 4 days
of incubation with 60 μM peptide. (A) Space-resolved confocal z-stack 1–20 over 9.2 μM,
step size: 0.46 μM. D-peptide: FAM staining (green): exc. 488 nm, em. 520 nm; cell nuclei:
TOPRO3 staining (red): exc. 633 nm, em. 660–670 nm. (B) panel 10 of z-stack shown in A;
separate localizations of KNT peptides on the membrane and in the cytosol are shown in
green but no peptide localization in the nuclei is visible (arrows).
(TIF)
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S3 Fig. Representative distribution of TD28-FAM in the N2aK18ΔK280 cell body after 4 days
of incubation with 60 μM peptide. (A): Space-resolved confocal z-stack 1–20 over 10.2 μM,
step size: 0.51 μM. D-peptide: FAM staining (green): exc. 488 nm, em. 520 nm; cell nuclei:
TOPRO3 staining (red): exc. 633 nm, em. 660–670 nm. (B): panel 10 of z-stack shown in S3A).
Diffuse localization of TD28 peptide on the membrane and cytosol are shown in green whereas
co localization in the nucleus appears in yellow (merge of FAM- and TOPRO3 staining; S3B
arrows).
(TIF)
S4 Fig. Treatment of inducible N2aTauK18ΔK280 cells with D-peptides. The bar diagram
shows the relative amount of Thioflavin S positive cells when treated with increasing amounts
of the tested D-peptides for 4 days (entry #3–16), compared to the untreated control (entry #2,
set to 100%, dashed line), as quantified by FACS. In the case of peptides APT and KNT a
small decrease in the number of ThS-positive cells was detected (e.g. 8.5% at 60 μM Apt,
entry#5 and 9.5% at 20 μM Knt-peptide, entry#7; marked with arrows), whereas treatment
with TL28 shows no reduction of ThS-positive cells. In contrast the treatment with TD28rev
(10–30 μM) increased the number of ThS-positive cells up to 240% compared with the
untreated control (entry#16).
(TIF)
S1 Materials and Methods. This file includes supporting materials and methods for S1 and
S4 Figs as well as supporting literature for S4 Fig.
(DOCX)
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